Parkman Healthcare Partners LLC Buys 11,028 Shares of Eli Lilly and Company $LLY

Key Points

• Parkman Healthcare Partners LLC increased its stake in Eli Lilly and Company by 39.2%, acquiring an additional 11,028 shares, which brings their total holdings to 39,191 shares valued at approximately $32.37 million.
• Several hedge funds significantly boosted their investments in Eli Lilly, with PNC Financial Services increasing its position by 97.5% and GAMMA Investing LLC by over 103,831% during the first quarter.
• Eli Lilly's recent earnings report showed an earnings per share (EPS) of $6.31 for the quarter, surpassing analyst estimates, and the company set its FY 2025 guidance between $21.750 and $23.000 EPS.

Parkman Healthcare Partners LLC increased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 39.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,191 shares of the company's stock after purchasing an additional 11,028 shares during the quarter. Eli Lilly and Company makes up about 3.8% of Parkman Healthcare Partners LLC's portfolio, making the stock its 3rd biggest position. Parkman Healthcare Partners LLC's holdings in Eli Lilly and Company were worth $32,368,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of LLY. WestEnd Advisors LLC grew its stake in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC bought a new position in Eli Lilly and Company in the first quarter worth approximately $27,000. Citizens National Bank Trust Department grew its stake in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new stake in Eli Lilly and Company during the first quarter worth $40,000. Finally, Mascagni Wealth Management Inc. purchased a new stake in Eli Lilly and Company during the fourth quarter worth $43,000. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Down 2.2%

Shares of LLY traded down $16.56 during midday trading on Friday, hitting $726.35. 3,953,474 shares of the company's stock traded hands, compared to its average volume of 4,774,109. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $942.35. The firm's fifty day moving average is $743.84 and its 200-day moving average is $780.58. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $687.46 billion, a price-to-earnings ratio of 47.47, a price-to-earnings-growth ratio of 1.01 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the business posted $3.92 EPS. The business's revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is presently 39.22%.

Insider Transactions at Eli Lilly and Company

In other news, Director Jamere Jackson bought 200 shares of the business's stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the transaction, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director J Erik Fyrwald bought 1,565 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock worth $2,894,841 over the last 90 days. Insiders own 0.14% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Guggenheim lowered their target price on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a report on Wednesday, August 13th. Deutsche Bank Aktiengesellschaft lowered their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a report on Monday, August 11th. Wall Street Zen upgraded Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 30th. Hsbc Global Res upgraded Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a report on Wednesday, August 27th. Finally, Leerink Partnrs lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $950.17.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.